Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2017-01-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PPROM-related morbidity and mortality is higher in the neonate than in the mother, especially in case of intrauterine inflammation. Of note, the most common biomarkers like CRP and leucocytes are not specific for uterine infections and have not been proven useful in these particular cases. Studies in intensive care medicine could show that there is a possible correlation between onset of infection and body-core-temperature.
The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility.
Twenty patients with verified PPROM between gestation week 22 and 27 should be included in this study. After gynecological and physical examination within verification of PPROM women will be informed and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
The investigators aim to describe a possible correlation between core-temperature and common biomarkers in clinical use for the detection of chorioamnionitis in patients with PPROM to possibly assess the optimal time for delivery subsequently.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL)
NCT04237142
Cervical Ripening in Premature Rupture of Membranes
NCT02314728
Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term
NCT01633294
Tearing of Membranes Before Birth - a Comparison Between Two Ways of Induction of Labor Pitocin Opposite Prostaglandin
NCT02720978
Premature Rupture of Membranes at 34 to 37 Weeks' Gestation
NCT03689062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PPROM occurs in 3 percent of pregnancies and is associated with one third of preterm births. There are multiple risk-factors for PPROM as maternal physiologic, genetic, and environmental as well as life-style factors. Of note, history of PPROM in a previous pregnancy, antepartum bleeding, cigarette smoking and genital tract infections, as the single most identifiable risk factor, are strongly associated with PPROM.
PPROM is diagnosed by the clinical loss of fluid from the cervical os. In case of not immediately visible amniotic fluid loss during the gynecological inspection, it can be diagnosed by ultrasound and verified by tests like the Amnisure© or the Fertisave© which detect the alpha microgloubulin 1 or the IGF binding protein of the fetal membranes.
Referring to a randomized controlled trial, the majority of pregnancies with PPROM deliver within one week of membrane rupture.
PPROM-related morbidity and mortality, which depends on gestational age, is higher in the neonate than in the mother, especially in case of intrauterine inflammation. Pulmonary hypoplasia, facial and orthopedic deformation can be the cause of prolonged, early PPROMS.
As the incidence of infection is higher at earlier gestational ages, up to one third of women with PPROM develop serious infections, including chorioamnionitis, endometritis and septicemia. Responsible bacterias are enterococcus, staphylococcus or anaerobic species.
The goal of antibiotic prophylaxis/therapy in PPROM is to reduce maternal and neonatal morbidity and mortality. Women should be observed for signs of infection, including maternal temperature, fetal heart rate, uterine contractions, and periodically common clinical infection markers. As the most common biomarkers like CRP and leucocytes are not specific for uterine infections, they have not been proven useful in these particular cases.
Prematurity is the crucial risk to the fetus with PPROM in the absence of complications like infection, before 34 weeks of gestation. Therefore, expectative management of uncomplicated PPROM-pregnancies at this gestational age is routinely used. This includes blood cell and infection monitoring, avoiding vaginal manipulation, antibiotic prophylaxis/treatment and corticosteroids.
After having reached gestational week 34+ induction of labour is routinely performed, without induction of lung maturity. The goal is a quick reaction to a chorioamnionitis with a prompt delivery.
Materials and Methods This study is conducted as a single centre pilot study in patients with PPROM. The study was approved by the local ethics committee of the Medical University of Vienna (IRB number: 1031/2014). Study center is the Department of Obstetrics and Gynecology of the Medical Universitiy of Vienna General Hospital.
Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensored thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
As there is no change of common PPROM-therapy, only clinical standard parameters will lead to the termination of pregnancy. Directly before delivery the OvulaRing® will be removed and the sensor-data will be analyzed with a special software.
Hypothesis In this pilot study, the investigators aim to describe a possible correlation between core-temperature and common biomarkers in clinical use for the detection of chorioamnionitis in patients with PPROM to possibly assess the optimal time for delivery.
A correlation between temperature and CRP, leucocytes and IL-6 should be explored. Later on, these facts may be used to optimize the standard procedures for a PPROM.
In some studies there is pointed out that there is a need for new parameters for chorioamnionitis. Maybe temperature monitoring can become such a new biomarker.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OvulaRing®
Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
OvulaRing®
The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OvulaRing®
The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* verified PPROM
* gestation week 22 to 27
* signed informed consent (ICF)
Exclusion Criteria
* Patient's age under 18 years
* Allergy to epoxide resin or ethylene vinyl acetate (EVA)-Copolymer
18 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Obstetrics and Gynaecology Clinic Narodni Front
OTHER
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Associate Prof. Ljubomir Petricevic MD
Ass. Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ljubomir Petricevic, Ass. Prof. M.D.
Role: PRINCIPAL_INVESTIGATOR
Medical University of Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Obstetrics and Gynecology, Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0012014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.